Lymphoma, Non-Hodgkin
Showing NaN - NaN of 17
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (BAY80-6946)
- +7 more
-
Chandler, Arizona
- +199 more
Jan 31, 2023
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (JNJ-75348780)
Recruiting
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
-
Birmingham, Alabama
- +43 more
Jan 27, 2023
Lymphoma, Non-Hodgkin Trial in Worldwide (Standard of Care, JCAR017)
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Standard of Care
- JCAR017
-
Phoenix, Arizona
- +78 more
Jan 13, 2023
Lymphoma, Non-Hodgkin Trial in Worldwide (Ibrutinib, Rituximab, Ifosfamide)
Lymphoma, Non-Hodgkin, Hodgkin Disease Trial in Worldwide (Relatlimab, Nivolumab)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- Hodgkin Disease
-
Phoenix, Arizona
- +53 more
Aug 17, 2022
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia Trial in Worldwide (JNJ-64264681, JNJ-67856633)
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
-
Stony Brook, New York
- +27 more
Aug 11, 2022
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell Trial in Worldwide (Ibrutinib)
Enrolling by invitation
- Lymphoma, B-Cell
- +4 more
-
Burbank, California
- +90 more
Mar 31, 2022
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (Aliqopa, BAY80-6946))
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Birmingham, Alabama
- +100 more
Feb 10, 2022
Lymphoma, Non-Hodgkin Trial in Worldwide (ABP 798, Rituximab)
Completed
- Lymphoma, Non-Hodgkin
- ABP 798
- Rituximab
-
Encinitas, California
- +97 more
Aug 7, 2020
Lymphoma, Non-Hodgkin Trial in Worldwide (Venetoclax, Cyclophosphamide, Obinutuzumab)
Lymphoma, Non-Hodgkin Trial in Worldwide (Inotuzumab ozogamicin, Rituximab, rituximab + gemcitabine)
Terminated
- Lymphoma, Non-Hodgkin
- Inotuzumab ozogamicin
- +3 more
-
Burbank, California
- +176 more
Dec 19, 2018
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in Worldwide (SGN-40, , rituximab)
Terminated
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- SGN-40
- +5 more
-
Birmingham, Alabama
- +65 more
Feb 6, 2015
Lymphoma, Non-Hodgkin Trial in Worldwide (Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128), no treatment)
Completed
- Lymphoma, Non-Hodgkin
- Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)
- no treatment
-
Antwerpen, Belgium
- +94 more
Nov 26, 2008